ART-CARMA
Research type
Research Study
Full title
ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA)
IRAS ID
304278
Contact name
Jonna Kuntsi
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
3 years, 3 months, 28 days
Research summary
Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder, with a prevalence among adults of 2.5%. The disorder is diagnosed based on impairing levels of inattentive, hyperactive and impulsive behaviours. Most adults with ADHD present with additional serious mental health problems. Emerging evidence further points at substantial comorbidity and shared genetics between adult ADHD and cardiometabolic diseases. However, detailed knowledge about the screening, diagnosis and clinical management of adults with ADHD and co-occurring cardiometabolic disease is lacking. The purpose of ART-CARMA is to (1) obtain real-world data from the patient’s daily life on the extent to which ADHD medication treatment and physical activity, individually and jointly, may influence cardiometabolic risks in adults with ADHD, and (2) obtain real-world data from the patient’s daily life on adherence to pharmacological treatment and its predictors and correlates, over a remote monitoring period of 12 months that starts from pre-treatment initiation.
ART-CARMA will benefit from the ADHD Remote Technology (‘ART’) assessment and monitoring battery for adults with ADHD (developed by Kuntsi, Dobson, et al.), and the RADAR-base mobile-health platform to which it is linked (developed by Dobson et al; http://www.radar-base.org). ART consists of both active (smartphone active app) and passive (smartphone passive app and a wearable device) monitoring. ART-CARMA will use remote measurement technology (RMT) in adults with ADHD to carry out unobtrusive, real-time data collection over an ongoing period of 12 months. By recruiting 150 adults from adult ADHD clinic waiting lists (and 150 of their informants) and monitoring them remotely, we will obtain objectively measured data relevant to cardiometabolic risk profiles from the patient’s daily life. By targeting the informative period from pre-treatment initiation through to treatment initiation, titration and the subsequent period, up to 12 months in total, we obtain real-time data on multiple parameters, including side effects, that can inform the personalisation of treatment.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
21/LO/0825
Date of REC Opinion
20 Dec 2021
REC opinion
Further Information Favourable Opinion